Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver

Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor... Case Report Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver 1,2 2 3 2 Junichi Okada, Shunichi Matsumoto, Kyoichi Kaira, Tsugumichi Saito, 2 4 5 6 Eijiro Yamada, Hideaki Yokoo, Ryuji Katoh, Motoyasu Kusano, 2 2 Shuichi Okada, Masanobu Yamada Clinical Clinical Practice Practice Points Points A 69-year-old male patient had been regularly visiting  His cancer cells had become resistant to 2 combina- our hospital to manage his sigmoid colon cancer with tion chemotherapy regimens; thus, monotherapy with multiple liver metastases since he had undergone cetuximab was started. resection of primary sigmoid colon cancer at age 64  With the latter regimen, his glucose metabolism years. remained stable with daily oral absorption of He developed postprandial hyperglycemia from ste- dapagliflozin. roid administration during chemotherapy and was  One month later, his carcinoembryonic antigen level referred to our outpatient clinic. had decreased dramatically from 1104 to 112.4 ng/mL, Because he was already receiving insulin therapy, we and computed tomography showed that his metastatic adjusted his insulin dosage and added a sodium glucose tumor lesions had shrunk substantially, suggesting the cotransporter (SGLT2) inhibitor (dapagliflozin; 5 mg/day). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Colorectal Cancer Elsevier

Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver

Loading next page...
 
/lp/elsevier/sodium-glucose-cotransporter-2-inhibition-combined-with-cetuximab-0j070gy0UW
Publisher
Elsevier
Copyright
Copyright © 2017 Elsevier Inc.
ISSN
1533-0028
eISSN
1936-0674
D.O.I.
10.1016/j.clcc.2017.09.005
Publisher site
See Article on Publisher Site

Abstract

Case Report Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver 1,2 2 3 2 Junichi Okada, Shunichi Matsumoto, Kyoichi Kaira, Tsugumichi Saito, 2 4 5 6 Eijiro Yamada, Hideaki Yokoo, Ryuji Katoh, Motoyasu Kusano, 2 2 Shuichi Okada, Masanobu Yamada Clinical Clinical Practice Practice Points Points A 69-year-old male patient had been regularly visiting  His cancer cells had become resistant to 2 combina- our hospital to manage his sigmoid colon cancer with tion chemotherapy regimens; thus, monotherapy with multiple liver metastases since he had undergone cetuximab was started. resection of primary sigmoid colon cancer at age 64  With the latter regimen, his glucose metabolism years. remained stable with daily oral absorption of He developed postprandial hyperglycemia from ste- dapagliflozin. roid administration during chemotherapy and was  One month later, his carcinoembryonic antigen level referred to our outpatient clinic. had decreased dramatically from 1104 to 112.4 ng/mL, Because he was already receiving insulin therapy, we and computed tomography showed that his metastatic adjusted his insulin dosage and added a sodium glucose tumor lesions had shrunk substantially, suggesting the cotransporter (SGLT2) inhibitor (dapagliflozin; 5 mg/day).

Journal

Clinical Colorectal CancerElsevier

Published: Mar 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off